SCHEMBL5207035

SCHEMBL5207035

COC(=O)c1ccccc1Nc1ccc2c(C=Nn3cccc3)nn(COCC[Si](C)(C)C)c2c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.36
ALOX15 P16050 1/20 0.36
NPC1 O15118 1/20 0.34
TP53 P04637 1/20 0.33
POLB P06746 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
ALDH1A1 P00352 4/20 0.33
HPGD P15428 1/20 0.33
SMN1; SMN2 Q16637 4/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
KDM4E B2RXH2 3/20 0.32
AHR P35869 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
GAA P10253 1/20 0.31
PTK2 Q05397 4/20 0.31
SIRT2 Q8IXJ6 1/20 0.31
MAPK1 P28482 2/20 0.31
PPARG P37231 1/20 0.31
NCOA2 Q15596 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5207031 1.00 MAPT (0.36) MAPTALOX15NPC1TP53POLB
SCHEMBL5207166 0.93 CTSV (0.35) MAPTNPC1TP53TDP1ALDH1A1
SCHEMBL5205340 0.85 KDR (0.34) KDR
SCHEMBL5206512 0.85 KDR (0.31) KDR
SCHEMBL6070247 0.85 NPC1 (0.34) MAPTALOX15NPC1TP53POLB
SCHEMBL5209255 0.84 KDR (0.33) KDR
SCHEMBL5206522 0.76 ALOX15 (0.35) MAPTALOX15NPC1ALDH1A1HPGD
SCHEMBL5249003 0.74 CHEK1 (0.44) MAPT
SCHEMBL5248999 0.74 CHEK1 (0.44) MAPT
SCHEMBL5249540 0.74 KDR (0.49) MAPTAURKAKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1585743-B1 2-(1H-INDAZOL-6-YLAMINO)- BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTHALMIC DISEASES PFIZER (US) 2007-05-23 EP disclosed
US-20060160858-A1 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS INC. 2006-07-20 US disclosed
EP-1585743-A1 2-(1H-INDAZOL-6-YLAMINO)- BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTHALMIC DISEASES PFIZER INC. (US) 2005-10-19 EP disclosed
WO-2004056806-A1 2-(1H-INDAZOL-6-YLAMINO)-BENZAMIDE COMPOUNDS AS PROTEIN KINASES INHIBITORS USEFUL FOR THE TREATMENT OF OPHTALMIC DISEASES PFIZER INC. (US) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160858-A1 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use CDK3, BRAF, CNKSR1 MAPT 921/4885ALOX15 2252/4885NPC1 3489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.